Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; iron oxide yellow; macrogol 400; hypromellose; titanium dioxide; iron oxide red; microcrystalline cellulose - treatment of osteoporosis. treatment of glucocorticoid induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 35 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; stearic acid; purified talc; microcrystalline cellulose; triethyl citrate; iron oxide yellow; magnesium stearate; disodium edetate; methacrylic acid - ethyl acrylate copolymer (1:1); sodium starch glycollate type a; simethicone; colloidal anhydrous silica - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long term corticosteroid therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium, quantity: 35 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; sorbitol; microcrystalline cellulose; sodium stearylfumarate - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long-term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: lactose; hyprolose; macrogol 8000; iron oxide yellow; iron oxide red; hypromellose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide - treatment of osteoporosis.,treatment of glucocorticoid-induced osteoporosis. ,preservation of bone mineral density in patients on long term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: lactose; macrogol 8000; colloidal anhydrous silica; titanium dioxide; magnesium stearate; hypromellose; iron oxide red; iron oxide yellow; crospovidone; hyprolose - treatment of osteoporosis.,treatment of glucocorticoid-induced osteoporosis. ,preservation of bone mineral density in patients on long term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: iron oxide yellow; hypromellose; lactose; titanium dioxide; magnesium stearate; crospovidone; colloidal anhydrous silica; macrogol 8000; iron oxide red; hyprolose - treatment of osteoporosis.,treatment of glucocorticoid-induced osteoporosis. ,preservation of bone mineral density in patients on long term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: hyprolose; lactose; macrogol 8000; colloidal anhydrous silica; titanium dioxide; hypromellose; crospovidone; magnesium stearate; iron oxide yellow; iron oxide red - treatment of osteoporosis.,treatment of glucocorticoid-induced osteoporosis. ,preservation of bone mineral density in patients on long term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.17 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; macrogol 8000; hypromellose; colloidal anhydrous silica; iron oxide yellow; iron oxide red; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 34.43 mg (equivalent: risedronate sodium, qty 30 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 400; titanium dioxide - treatment of paget?s disease of bone

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 5.74 mg (equivalent: risedronate sodium, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; hyprolose; titanium dioxide; hypromellose; macrogol 8000; colloidal anhydrous silica; iron oxide yellow; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy